Introduction to Genetic Technologies' groundbreaking announcement

Genetic Technologies Limited (ASX: $GTG) has launched a groundbreaking geneType Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to women above the age of 30, assesses the risk of cancer due to hereditary and sporadic disease, representing a significant leap in preventative healthcare.

Executive commentary on the geneType Comprehensive Risk Assessment test

We are incredibly proud to have been part of this 'Know Your Risk' event which underscored the importance of genetic testing and risk assessment in transforming women's health, inspiring attendees to advocate for their health and well-being proactively. We are also very fortunate and to have the opportunity to launch this unique risk assessment test in the presence of such a wonderful group of people.

Summary of Genetic Technologies' announcement

Genetic Technologies' launch of the geneType Comprehensive Risk Assessment test represents a significant advancement in personalized preventative healthcare. The test provides a complete understanding of a woman's risk profile for developing breast and ovarian cancer, with the ability to screen 100% of women at risk. With breast cancer affecting 1 in 8 women in the US and ovarian cancer being more deadly, this test holds immense potential for early diagnosis and ultimately saving lives. The company's strategic partners have expressed overwhelming excitement about the launch, and the CEO highlighted the importance of genetic testing and risk assessment in transforming women's health. Genetic Technologies has also prepared for significant demand by fully onboarding a high throughput automated laboratory in the United States with the capacity to scale up to run 100,000 tests per month if required. This announcement marks a significant milestone in the company's commitment to improving health outcomes through innovative genomics-based tests.